Pill versions of the successful GLP1 drugs from Novo Nordisk and Eli Lilly will likely be on the market in 2026’s first half.

NEW YORK -- A course of pills developed by Pfizer can slash the risk of being hospitalized or dying from COVID-19 by 89% if taken within three days of developing symptoms, according to results ...

More than a dozen pharmas have recently struck deals with the White House to lower drug prices. Nevertheless, drugmakers ...

Now, it’s worth noting Stock Advisor’s total average return is 971 % — a market-crushing outperformance compared to 196% for ...

CHICAGO -- Pfizer has begun a Phase 2 and 3 clinical trial of its COVID-19 antiviral treatment, Paxlovid, in children ages 6 to 17, the company said Wednesday in a news release. The study will ...

Pharmacists can prescribe the leading COVID-19 pill directly to patients under a new U.S. policy announced Wednesday that's intended to expand use of Pfizer's drug Paxlovid. The Food and Drug ...

More change is on the way, including from Novo Nordisk, but if you have a contrarian bent, you might prefer out-of-favor drug makers Bristol Myers Squibb(NYSE: BMY), Merck(NYSE: MRK), and Pfizer(NYSE: ...

The US drug regulator approved a daily pill version of Novo Nordisk’s Wegovy injection, giving the Danish drugmaker a head start as the first to market in the next big competitive frontier in ...

Initiatives from former President Joe Biden and current President Donald Trump have been effective in reducing the prices of ...